نتایج جستجو برای: hpv16 l1 vlp

تعداد نتایج: 35265  

2016
Maryam Zahin Joongho Joh Sujita Khanal Adam Husk Hugh Mason Heribert Warzecha Shin-je Ghim Donald M. Miller Nobuyuki Matoba Alfred Bennett Jenson

Cervical cancer is the most common malignancy among women particularly in developing countries, with human papillomavirus (HPV) 16 causing 50% of invasive cervical cancers. A plant-based HPV vaccine is an alternative to the currently available virus-like particle (VLP) vaccines, and would be much less expensive. We optimized methods to express HPV16 L1 protein and purify VLPs from tobacco (Nico...

Journal: :Journal of the National Cancer Institute 2001
C D Harro Y Y Pang R B Roden A Hildesheim Z Wang M J Reynolds T C Mast R Robinson B R Murphy R A Karron J Dillner J T Schiller D R Lowy

BACKGROUND Studies in animal models have shown that systemic immunization with a papillomavirus virus-like particle (VLP) vaccine composed of L1, a major structural viral protein, can confer protection against subsequent experimental challenge with the homologous virus. Here we report results of a double-blind, placebo-controlled, dose-escalation trial to evaluate the safety and immunogenicity ...

2015
Bettina Huber Christina Schellenbacher Christoph Jindra Dieter Fink Saeed Shafti-Keramat Reinhard Kirnbauer

Persistent infection with oncogenic human papillomaviruses (HPV) types causes all cervical and a subset of other anogenital and oropharyngeal carcinomas. Four high-risk (hr) mucosal types HPV16, 18, 45, or 59 cause almost all cervical adenocarcinomas (AC), a subset of cervical cancer (CxC). Although the incidence of cervical squamous cell carcinoma (SCC) has dramatically decreased following int...

Journal: :Vaccine 2004
Kevin A Ault Anna R Giuliano Robert P Edwards Gretchen Tamms Lee-Lian Kim Judith F Smith Kathrin U Jansen Maria Allende Frank J Taddeo DeeMarie Skulsky Eliav Barr

Human papillomavirus (HPV) infection can cause genital warts and cervical cancer. HPV types 6 and 11 cause >90% of genital wart cases; HPV16 and 18 cause 70% of cervical cancers. A prophylactic HPV (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine may substantially reduce the incidence of these lesions. This report describes the results of a phase I study of the HPV18 component of such...

Journal: :Journal of immunology 2004
Rongcun Yang Francisco Martinez Murillo Ken-Yu Lin William H Yutzy Satoshi Uematsu Kiyoshi Takeda Shizuo Akira Raphael P Viscidi Richard B S Roden

Human papillomavirus type-16 (HPV16) L1 virus-like particles (VLPs) activate dendritic cells (DCs) and induce protective immunity. In this study, we demonstrate, using global gene expression analysis, that HPV16 VLPs produce quite distinct innate responses in murine splenic DC subpopulations. While HPV16 VLPs increase transcription of IFN-gamma and numerous Th1-related cytokines and chemokines ...

Journal: :Cancer prevention research 2013
Mahboobeh Safaeian Carolina Porras Yuanji Pan Aimee Kreimer John T Schiller Paula Gonzalez Douglas R Lowy Sholom Wacholder Mark Schiffman Ana C Rodriguez Rolando Herrero Troy Kemp Gloriana Shelton Wim Quint Leen-Jan van Doorn Allan Hildesheim Ligia A Pinto

The Costa Rica HPV16/18 Vaccine Trial (CVT) showed that four-year vaccine efficacy against 12-month HPV16/18 persistent infection was similarly high among women who received one, two, or the recommended three doses of the bivalent HPV16/18 L1 virus-like particle (VLP) vaccine. Live-attenuated viral vaccines, but not simple-subunit vaccines, usually induce durable lifelong antibody responses aft...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 1998
H L Greenstone J D Nieland K E de Visser M L De Bruijn R Kirnbauer R B Roden D R Lowy W M Kast J T Schiller

Papillomavirus-like particles (VLPs) are a promising prophylactic vaccine candidate to prevent human papillomavirus (HPV) infections and associated epithelial neoplasia. However, they are unlikely to have therapeutic effects because the virion capsid proteins are not detected in the proliferating cells of the infected epithelia or in cervical carcinomas. To increase the number of viral antigen ...

Journal: :Acta biochimica et biophysica Sinica 2005
Hong-Li Liu Wen-Sheng Li Ting Lei Jing Zheng Zheng Zhang Xiao-Fei Yan Zhe-Zhi Wang Yi-Li Wang Lü-Sheng Si

To develop a plant expression system for the production of the human papillomavirus type 16 (HPV16) vaccine, we investigated whether the HPV16 L1 protein can be expressed in tobacco plants and whether it can be used as the cheapest form of edible vaccine. The HPV16 L1 coding sequence was amplified by PCR using specific primers from the plasmid pGEM-T-HPV16 containing the template sequence, and ...

2013
Christina Schellenbacher Kihyuck Kwak Dieter Fink Saeed Shafti-Keramat Bettina Huber Christoph Jindra Helena Faust Joakim Dillner Richard B.S. Roden Reinhard Kirnbauer

Licensed human papillomavirus (HPV) vaccines, based on virus-like particles (VLPs) self-assembled from major capsid protein L1, afford type-restricted protection against HPV types 16/18/6/11 (or 16/18 for the bivalent vaccine), which cause 70% of cervical cancers (CxCas) and 90% of genital warts. However, they do not protect against less prevalent high-risk (HR) types causing 30% of CxCa, or cu...

پایان نامه :دانشگاه آزاد اسلامی - دانشگاه آزاد اسلامی واحد علوم دارویی 1392

سرطان دهانه رحم شایع ترین نوع سرطان موثر بر زنان در کشورهای در حال توسعه می باشد که توسط عفونت با ویروس پاپیلومای انسانی(hpv) ایجاد می شود. بیش از 50? از سرطان های دهانه رحم در سراسر جهان به hpv16 نسبت داده شده است. l1پروتئین عمده کپسید و l2 پروتئین جزئی کپسید hpv است. پروتئینl1 قادر است به صورت خود به خودی به ذرات شبه ویروسی (vlp) فاقد dna ژنومی مونتاژ شود. در حال حاضر امیدوار کننده ترین واکسن...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید